- Home
- Automated
- List of product information
- MONTAS-10 FILM COATED TABLET 10 MG [SIN16364P]
MONTAS-10 FILM COATED TABLET 10 MG [SIN16364P]
Active ingredients: MONTAS-10 FILM COATED TABLET 10 MG
Product Info
MONTAS-10 FILM COATED TABLET 10 MG
[SIN16364P]
Product information
Active Ingredient and Strength | MONTELUKAST SODIUM EQV. MONTELUKAST - 10 MG |
Dosage Form | TABLET, FILM COATED |
Manufacturer and Country | INTAS PHARMACEUTICALS LIMITED (SITE I) - INDIA |
Registration Number | SIN16364P |
Licence Holder | ACCORD HEALTHCARE PRIVATE LIMITED |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | R03DC03 |
4.1 Therapeutic indications
Montelukast is indicated in adult and pediatric patients 1 year of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day- and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction.
Montelukast is indicated for the relief of daytime and nighttime symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adults and pediatric patients 1 year of age and older). Because the benefits of Montelukast may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis, reserve use for patients who have an inadequate response or intolerance to alternative therapies.
4.2 Posology and method of administration*
Montelukast Tablet should be taken once daily. For asthma, the dose should be taken in the evening. For allergic rhinitis, the time of administration may be individualized to suit patient needs.
Patients with both asthma and allergic rhinitis should take only one tablet daily in the evening.
Adults 15 Years of Age and Older with Asthma and/or Allergic rhinitis
The dosage for adults 15 years of age and older is one 10-mg tablet daily.
Pediatric Patients 6 to 14 Years of Age with Asthma and/or Allergic rhinitis
The dosage for pediatric patients 6 to 14 years of age is one 5-mg chewable tablet daily.
Pediatric Patients 2 to 5 Years of Age with Asthma and/or Allergic rhinitis
The dosage for pediatric patients 2 to 5 years of age is one 4-mg chewable tablet daily or one packet of 4-mg oral granules daily.
Pediatric Patients 1 to 2 Years of Age with Asthma
The dosage for pediatric patients 1 to 2 years of age is one packet of 4-mg oral granules daily to be taken in the evening.
Pediatric Patients 1 Year to 2 Years of Age with Perennial Allergic Rhinitis
The dosage for pediatric patients 1 year to 2 years of age is one packet of 4-mg oral granules daily.
General Recommendations
The therapeutic effect of Montelukast Tablet on parameters of asthma control occurs within one day. Montelukast Tablet tablets and chewable tablets can be taken with or without food. Patients should be advised to continue taking Montelukast Tablet while their asthma is controlled, as well as during periods of worsening asthma.
No dosage adjustment is necessary for pediatric patients, the elderly, for patients with renal insufficiency, or mild-to-moderate hepatic impairment, or for patients of either gender.
Therapy with Montelukast in Relation to Other Treatments for Asthma
Montelukast can be added to a patient's existing treatment regimen. Reduction in Concomitant Therapy:
Bronchodilator Treatments: Montelukast can be added to the treatment regimen of patients who are not adequately controlled on bronchodilator alone. When a clinical response is evident (usually after the first dose), the patient's bronchodilator therapy can be reduced as tolerated.
Inhaled Corticosteroids: Treatment with Montelukast provides additional clinical benefit to patients treated with inhaled corticosteroids. A reduction in the corticosteroid dose can be made as tolerated. The dose should be reduced gradually with medical supervision. In some patients, the dose of inhaled corticosteroids can be tapered off completely. Montelukast should not be abruptly substituted for inhaled corticosteroids.
*Kindly note that not all presentations are marketed locally.
4.3 Contraindications
Hypersensitivity to any component of this product.
